Navigation Links
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
Date:8/27/2008

SAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Theodore Schroeder will present the company's corporate overview on Thursday, September 4 at 4:00pm Eastern Time (1:00pm Pacific Time) during the 2008 NewsMakers In the Biotech Industry Conference at the Millennium Broadway Hotel in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company currently has two Phase III product candidates in development, Acetavance(TM) (intravenous acetaminophen) for the treatment of acute pain and fever, and Omigard(TM) (omiganan pentahydrochloride 1% topical gel) for the prevention of catheter-related infections. For more information about Cadence's pipeline, visit http://www.cadencepharm.com.

Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence

Pharmaceuticals, Inc.

Contacts:

William R. LaRue Anna Gral
'/>"/>

SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
2. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
9. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...IK, Iceland, November 24 ...nced that it has received notice from,the Nasdaq S...tock will be,suspended as of November 30, 2009 and...nd Exchange Commission, which will remove deCODE,s...ompany files an appeal to the Nasdaq,Listing Quali...
(Date:11/24/2009)... /PRNewswire-Asia/ -- NOD Pharmaceuticals Inc. ann...has allowed the patent application for,its nano-pa... NOD technology is a highly efficient approach to ... nano-particles to enable oral delivery of drugs,o...y is a platform technology,that can be applied to ...
(Date:11/24/2009)...cently approved the Promega PowerPlex 16 HS System...ating DNA records for the National DNA Index Syste...EB) -- The FBI recently approved the Promega Powe...articipating in, or generating DNA records for, th... contains more than seven million profiles and has...
(Date:11/24/2009)...2009 Arena Pharmaceutica...he company is scheduled to present at the Piper Ja...er 1, 2009 at 11:30 a.m. Eastern Time (8:30 a.m. P...ork City. Jack Lief, Arena,s President and Chief E...iew of the company, including its clinical develop...
Breaking Biology Technology:deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 2deCODE Receives Delisting Notice From Nasdaq, Plans to Appeal 3NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2Arena Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 3
... Treatment Results in Improvements in Physical ...ife, SAN FRANCISCO, Oct. 27 More than half of pa...ctions of golimumab (CNTO 148),50 mg and 100 mg, a...mprovements in the joint and skin symptoms of acti...ults sustained through one year.,Golimumab-treated...
...ay, November 2, 2008 at this year,s liver meet...ember 4, SAN FRANCISCO, Oct. 27 Nonalcoholic ste...esity, and there is no approved,medical therapy fo...ers,tested the effects of weight reduction using a...To do so, 31 overweight or obese patients with NAS...
...ny Strengthens Board as Lead Products Approach ...ber 27 UK medical technology company,BioCeramic T...Richard Sykes,has accepted the role of Chairman of...an of pharmaceuticals company GlaxoSmithKline plc,...amic Therapeutics Ltd is a spinout from Imperial C...
Other Biology Technology:One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 2One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 3One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 4One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 5One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 6One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 7One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 8One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study 9Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health 2Sir Richard Sykes Joins BioCeramic Therapeutics as Chairman 2
(Date:11/25/2009)... , On September 11, firefighters, police officers...ffort in the World Trade Center complex. They batt..., searched for survivors, tackled fires and evacua...contained an estimated 17,000 people. And making t...unications: frightened workers and their relatives...
(Date:11/25/2009)... , LA JOLLA, CAWhen you eat may be just as vita...s at the Salk Institute for Biological Studies. Th...xing and waning of thousands of genes in the liver...lled by food intake and not by the body,s circadia...eding time determines the activity of a large numb...
(Date:11/24/2009)... , Stents that keep weakened and flabby arteries ...ter six months, those stents are no longer needed ... unnecessary. Previously, doctors had no choice bu...an of Tel Aviv University,s Department of Biomedic...fiber platform that carries drugs where they,re ne...
Breaking Biology News(10 mins):Magic box for mission impossible 2Magic box for mission impossible 3Feeding the clock 2Feeding the clock 3A coating for life 2Noted Diagnostic Radiologists Joan Werber D O Ahmed Farag M D C M Join Forces to Create Diagnostic Imaging Specialists of Chicago 6490 1NuVasive To Present at the Piper Jaffray Health Care Conference and the J P Morgan SMid Cap Conference 6488 1NuVasive To Present at the Piper Jaffray Health Care Conference and the J P Morgan SMid Cap Conference 6488 2NuVasive To Present at the Piper Jaffray Health Care Conference and the J P Morgan SMid Cap Conference 6488 3Immucor to Present at the Piper Jaffray 21st Annual Health Care Conference 6486 1
...cations Currently in Use, Including Large Scale, ...hcare Solutions to be ...rnational,Inc. (OTC Bulletin Board: BKYI), a leade...eless public safety, announced today that the comp...t biometric applications at,the 2007 Biometric Tec...
...unch of SAFmodule(TM) 3.1 SP3 to expand Novell, M...thentication methods, AUSTIN, Texas, Sept. 20 SA... biometric authentication to Novell(R) eDirectory,...ramework with Novell,s,Novell Modular Authenticati...a component of eDirectory, Novell,s market-leading...
...ernational team of scientists has produced a new t...efficiently than other rice crops. Professor Andy ...VBI) has been working with colleagues in India, In... to identify, characterize and make use of a gene ...important grain crop. The research, which was rece...
Other Biology News:BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo 2BIO-key(R) International to Showcase Deployed Biometric Security Applications at 2007 Biometric Technology Expo 3IdentiPHI Re Launches SAFmodule Software to Secure Novell(R) Networks 2HARDY rice: less water, more food 2HARDY rice: less water, more food 3
CORNING CELLSTACK VENTED CAP, 33MM, STERILE, 0.2UM MEMBRANE from Sigma-Aldrich
...ammable system automates the denaturation and hybr...and provides walk-away convenience for clinical an...wide range of sample types, is easy to use, and re...g overall precision and accuracy in all (F)ISH ass...
MaxPlax Lambda Packaging Extract from EPICENTRE Biotechnologies
...Iodide (PI) is a fluorescent nucleic acid dye whic... a nuclear counterstain, propidium iodide stains t...scent red color provides excellent contrast to gre.... Propidium Iodide can be used for fluorescent in...
Biology Products: